Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fidaxomicin has high in vitro activity against Mycobacterium tuberculosis.

Journal of medical microbiology - 1 Mar 2021

Sun Qing, Wang Shuqi, Liao Xinlei, Jiang Guanglu, Huang Hairong, Li Hao, Wang Guirong

Abstract excerpt

This study aimed to evaluate whether the antibiotic fidaxomicin has in vitro activity against Mycobacterium tuberculosis (Mtb). 38 fully drug-sensitive Mtb strains and 34 multidrug-resistant tuberculosis (MDR-TB) strains were tested using the microplate alamar blue assay (MABA) method to determine the minimum inhibitory concentrations (MICs) for fidaxomicin and rifampicin. Fidaxomicin has high in vitro activity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Bacterial Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Multiple, Bacterial

Share to Microbial Sensitivity Tests

Share to Mycobacterium tuberculosis

Share to Rifampin

Share to Tuberculosis

Share to Tuberculosis, Multidrug-Resistant

Source

Identifiers

PMID: 33593474
DOI: 10.1099/jmm.0.001324

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fidaxomicin has high in vitro activity against Mycobacterium tuberculosis.PMID 33593474Read ↗

Antimycobacterial drug discovery using Mycobacteria-infected amoebae identifies anti-infectives and new molecular targets.Semantic proximity Read ↗

Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.Semantic proximity Read ↗

In Vitro and In Vivo Efficacy of NITD-916 against Mycobacterium fortuitumSemantic proximity Read ↗

In vitro activities of contezolid (MRX-I) against drug-sensitive and drug-resistant Mycobacterium tuberculosisSemantic proximity Read ↗

The Repurposing of FDA-Approved Drugs as FtsZ Inhibitors against Mycobacterium tuberculosis: An In Silico and In Vitro StudySemantic proximity Read ↗

Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in ChinaSemantic proximity Read ↗

Comparison of the in vitro activity of linezolid, tedizolid, sutezolid, and delpazolid against rapidly growing mycobacteria isolated in Beijing, ChinaSemantic proximity Read ↗

Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis.Semantic proximity Read ↗

WQ-3810: A new fluoroquinolone with a high potential against fluoroquinolone-resistant Mycobacterium tuberculosis.Semantic proximity Read ↗

Comparative in vitro susceptibility of a novel fluoroquinolone antibiotic candidate WFQ-228, levofloxacin, and moxifloxacin against Mycobacterium tuberculosis.Semantic proximity Read ↗

In Vitro Activity of Tedizolid against Mycobacterium tuberculosisSemantic proximity Read ↗

New fluoroquinolones active against fluoroquinolones-resistant Mycobacterium tuberculosis strains.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.